We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Overview of patent-statutory subject matter in biotechnology

  • CCPIT Patent & Trademark Law Office
  • -
  • China, European Union, Japan, USA
  • -
  • April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound

Protection for medical-related inventions in Japan

  • Shiga International Patent Office
  • -
  • Japan
  • -
  • April 8 2013

Japan has the second largest medical market in the world. For instance, there has been active development in recent years concerning regenerative

Patent term extensions and regulatory exclusivities for pharmaceuticals in Asia and South America

  • Morrison & Foerster LLP
  • -
  • Argentina, Brazil, Chile, China, Hong Kong, Japan, Malaysia, Mexico, Philippines, South Korea, Thailand, USA, Vietnam
  • -
  • June 27 2012

Patent protection for pharmaceutical products has an impact on the pharmaceutical market and innovation